This is a single-arm, open-label clinical trial designed to assess the safety and therapeutic efficacy of iPSC-derived islet cell infusion in patients with diabetes mellitus.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria:
* Subjects aged 18 years or older, of any sex.
* Duration of diabetes \> 5 years.
* Body mass index (BMI) 18-35 kg/m².
* Receiving insulin therapy.
Key Exclusion Criteria:
* Presence of HIV infection , or active acute or chronic hepatitis infection (HBV or HCV), or Treponema pallidum infection.
* Active pulmonary tuberculosis or patients undergoing treatment for suspected tuberculosis.
* Uncontrolled systemic fungal, bacterial, viral, or other infections .
* Presence of severe diabetic complications.
* Presence of severe organic lesions in vital organs such as the heart, lungs, or brain.
* History of malignant tumors.
Primary outcome measure(s)
Adverse events — From enrollment to month 6
Trial sites (1)
Facility
City
Region
Status
Peking University First Hospital
Beijing
China
More Peking University First Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.